Elite Pharmaceuticals, Inc. (ELI) Initiates Pivotal Bioequivalence Study For Second Opioid Abuse Deterrent Product
1/14/2014 8:58:51 AM
NORTHVALE, N.J., Jan. 14, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") ("Elite") (OTCBB:ELTP) announced today the first dosing of a pivotal bioequivalence study in healthy volunteers for an undisclosed opioid abuse deterrent product utilizing Elite's proprietary pharmacological abuse deterrent technology.
Help employers find you! Check out all the jobs and post your resume.
comments powered by